doi: 10.3390/metabo15050322
Summary of Study Design for CT-996: The study is a Phase 1 clinical trial, multi-centered and randomized where the goal is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CT-996 in overweight or obese individuals as well as patients with Type 2 Diabetes Mellitus (T2DM)
Therefore, GIP functions as a bifunctional regulator that stabilizes blood glucose and has diverging, glucose-dependent effects on the two main pancreatic glucoregulatory hormones (Christensen et al., 2011)
The Complete FDA-Approved Criteria, Off-Label Use, and What Your Provider Actually Evaluates Tool: cost calculator Sources Rosenstock J et al
If the kidneys are strained, urine output may drop, and the urine may appear darker